Australia's most trusted
source of pharma news
Posted 7 May 2024 AM
A surge in chronic kidney disease (CKD) in Australia will cost the economy billions and increase associated environmental costs, according to research by AstraZeneca.
The pharma, which sponsors SGLT2 inhibitor Forxiga in Australia, which is indicated for CKD, presented the Multidimensional burden of chronic kidney disease in eight countries: Insights from the IMPACT CKD study at the 2024 ISN World Congress of Nephrology. The research was conducted by 12 international scientists, including Professor Stephen Chadban from the Royal Prince Alfred Hospital Department of Renal Medicine.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.